Anteris Technologies Global (NASDAQ:AVR) Major Shareholder L1 Capital Pty Ltd Acquires 236,354 Shares of Stock

Anteris Technologies Global Corp. (NASDAQ:AVR) major shareholder L1 Capital Pty Ltd purchased 236,354 shares of Anteris Technologies Global stock in a transaction on Friday, October 2nd. The stock was bought at an average cost of $7.78 per share, with a total value of $1,838,834.12. Following the completion of the acquisition, the insider owned 12,129,925 shares in the company, valued at approximately $94,370,816.50. This trade represents a 1.99% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

• On Monday, October 5th, L1 Capital Pty Ltd acquired 648,455 shares of Anteris Technologies Global stock. The shares were bought at an average price of $7.51 per share, for a total transaction of $4,869,897.05.
• On Thursday, October 1st, L1 Capital Pty Ltd acquired 322,940 shares of Anteris Technologies Global stock. The shares were bought at an average cost of $7.60 per share, with a total value of $2,454,344.00.
• On Wednesday, September 30th, L1 Capital Pty Ltd bought 74,286 shares of Anteris Technologies Global stock. The stock was bought at an average price of $7.72 per share, with a total value of $573,487.92.
• On Friday, August 28th, L1 Capital Pty Ltd sold 7,800 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.83, for a total transaction of $68,874.00.
• On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The stock was sold at an average price of $9.30, for a total value of $3,495,079.50.
• On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.10, for a total value of $2,291,780.40.
• On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.10, for a total value of $1,415,240.10.
• On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.30, for a total value of $3,989,046.40.
• On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.23, for a total value of $120,001.63.
• On Monday, August 3rd, L1 Capital Pty Ltd sold 475,693 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total value of $3,853,113.30.

Anteris Technologies Global Trading Down 6.6%

AVR opened at $7.05 on Wednesday. The stock’s 50 day simple moving average is $8.46 and its 200-day simple moving average is $8.01. The stock has a market cap of $687.08 million, a PE ratio of -3.62 and a beta of 1.87. Anteris Technologies Global Corp. has a 1 year low of $3.30 and a 1 year high of $11.06.

Anteris Technologies Global (NASDAQ:AVR) last issued its earnings results on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.09). Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%.The firm had revenue of $1.01 million during the quarter, compared to the consensus estimate of $1.50 million. During the same period last year, the business earned ($0.58) earnings per share. Equities analysts forecast that Anteris Technologies Global Corp. will post -1.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on AVR shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 target price on shares of Anteris Technologies Global in a research note on Friday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Finally, Barclays started coverage on Anteris Technologies Global in a research note on Tuesday. They issued a “positive” rating and a $10.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Anteris Technologies Global has an average rating of “Moderate Buy” and an average price target of $14.00.

Key Anteris Technologies Global News

Here are the key news stories impacting Anteris Technologies Global this week:

• Positive Sentiment: Major shareholder increased its stake. L1 Capital bought 648,455 shares at an average of $7.51, worth approximately $4.87 million, increasing its position by 5.35% to 12.78 million shares. The investor also purchased 236,354 shares on October 2 and additional shares in late September and early October, bringing recent buying to roughly 1.28 million shares worth $9.7 million. This may support investor confidence because a large shareholder is committing substantial capital despite recent weakness. Anteris Technologies Global insider buying report
• Positive Sentiment: Analyst coverage is generally favorable. Barclays initiated coverage with a positive rating and a $10 price target, while Cantor Fitzgerald maintained an overweight rating and a $15 target. The reported consensus rating is “Moderate Buy,” with an average target of $14, substantially above the recent trading level. Anteris Technologies Global analyst and stock report
• Neutral Sentiment: Share and equity-incentive records were updated. Anteris reported a slight decrease in CHESS Depositary Interests and the lapse or cessation of several restricted stock unit and option tranches. The changes may affect the share count and potential dilution, but the filings did not indicate a new operating or clinical catalyst. Anteris Technologies CDI and equity incentive update
• Negative Sentiment: Fundamentals remain weak. The latest quarterly results missed expectations, with a $0.30 per-share loss versus the forecast $0.21 loss and revenue of $1.01 million versus the $1.50 million estimate. Anteris remains unprofitable, and analysts expect a full-year loss. Shares also remain below their 50-day and 200-day moving averages, reflecting continued technical pressure. Anteris Technologies Global earnings and performance report

Institutional Investors Weigh In On Anteris Technologies Global

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Anteris Technologies Global in the second quarter valued at about $56,846,000. Nantahala Capital Management LLC bought a new position in shares of Anteris Technologies Global in the second quarter valued at approximately $33,325,850. ADAR1 Capital Management LLC bought a new position in shares of Anteris Technologies Global in the second quarter valued at approximately $30,979,000. Perceptive Advisors LLC boosted its holdings in shares of Anteris Technologies Global by 104.4% in the 1st quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock worth $19,011,000 after acquiring an additional 1,750,000 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new position in shares of Anteris Technologies Global in the 2nd quarter worth approximately $6,350,000.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.